2025 FDA GLP-1 Shortage Response
from GLP-1 Studio Podcast Hosted by Amanda Bonello
GLP-1 Studio Podcast – Studio Special Host: Amanda Bonello In this Studio Special, I'm sharing advocacy work I originally created through the GLP-1 Collective, where I serve as founder and executive director. This statement was part of our ongoing effort to ensure patient voices are heard in federal decision-making around the GLP-1 medication shortage. The shortage crisis has forced patients into impossible situations—choosing between financial devastation and leaving a chronic disease untreated, or turning to unsafe alternatives when every legitimate access point fails them. This isn't acceptable, and it isn't something patients should navigate alone. This piece calls on the FDA to respond with the urgency this moment demands while maintaining scientific rigor. Patients deserve a seat at the table when decisions directly impact their health, safety, and future. In this episode: Why coordinated federal response matters for patient safety The real-world consequences when access points fail What transparent, patient-centered FDA leadership looks like How communities are organizing for change Connect with Amanda Bonello and the GLP-1 Studio Podcast: Learn more at GLP1Studio.com Disclaimer: This content is not medical advice. I am not paid by pharmaceutical or compounding pharmacy companies. All opinions expressed are my own. Any affiliate links are clearly disclosed. Get full access to GLP-1 Studio at newsletter.glp1studio.com/subscribe
Embed this episode
No transcript yet.